Literature DB >> 35553342

The role of PFKFB3 in maintaining colorectal cancer cell proliferation and stemness.

Siyuan Yan1, Qianqian Li2, Shi Li2, Zhiying Ai2, Dongdong Yuan3.   

Abstract

Since generally confronting with the hypoxic and stressful microenvironment, cancer cells alter their glucose metabolism pattern to glycolysis to sustain the continuous proliferation and vigorous biological activities. Bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2/FBPase-2) isoform 3 (PFKFB3) functions as an effectively modulator of glycolysis and also participates in regulating angiogenesis, cell death and cell stemness. Meanwhile, PFKFB3 is highly expressed in a variety of cancer cells, and can be activated by several regulatory factors, such as hypoxia, inflammation and cellular signals. In colorectal cancer (CRC) cells, PFKFB3 not only has the property of high expression, but also probably relate to inflammation-cancer transformation. Recent studies indicate that PFKFB3 is involved in chemoradiotherapy resistance as well, such as breast cancer, endometrial cancer and CRC. Cancer stem cells (CSCs) are self-renewable cell types that contribute to oncogenesis, metastasis and relapse. Several studies indicate that CSCs utilize glycolysis to fulfill their energetic and biosynthetic demands in order to maintain rapid proliferation and adapt to the tumor microenvironment changes. In addition, elevated PFKFB3 has been reported to correlate with self-renewal and metastatic outgrowth in numerous kinds of CSCs. This review summarizes our current understanding of PFKFB3 roles in modulating cancer metabolism to maintain cell proliferation and stemness, and discusses its feasibility as a potential target for the discovery of antineoplastic agents, especially in CRC.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Colorectal cancer; Glycolysis; PFKFB3; Proliferation; Stemness

Mesh:

Substances:

Year:  2022        PMID: 35553342     DOI: 10.1007/s11033-022-07513-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  88 in total

1.  Tissue-specific structure/function differentiation of the liver isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.

Authors:  Yong-Hwan Lee; Yang Li; Kosaku Uyeda; Charles A Hasemann
Journal:  J Biol Chem       Date:  2002-10-11       Impact factor: 5.157

Review 2.  Techniques to monitor glycolysis.

Authors:  Tara TeSlaa; Michael A Teitell
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

3.  An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect.

Authors:  J Chesney; R Mitchell; F Benigni; M Bacher; L Spiegel; Y Al-Abed; J H Han; C Metz; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

5.  Endothelial PFKFB3 plays a critical role in angiogenesis.

Authors:  Yiming Xu; Xiaofei An; Xin Guo; Tsadik Ghebreamlak Habtetsion; Yong Wang; Xizhen Xu; Sridhar Kandala; Qinkai Li; Honggui Li; Chunxiang Zhang; Ruth B Caldwell; David J Fulton; Yunchao Su; Md Nasrul Hoda; Gang Zhou; Chaodong Wu; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-04-03       Impact factor: 8.311

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase.

Authors:  E Van Schaftingen; L Hue; H G Hers
Journal:  Biochem J       Date:  1980-12-15       Impact factor: 3.857

8.  AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.

Authors:  Kun Liu; Yan-Chi Li; Yu Chen; Xiao-Bao Shi; Zi-Hao Xing; Zheng-Jie He; Sheng-Te Wang; Wei-Jing Liu; Peng-Wei Zhang; Ze-Zhong Yu; Xue-Mei Mo; Mei-Wan Chen; Zhe-Sheng Chen; Zhi Shi
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

9.  Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism.

Authors:  Susana Ros; Almut Schulze
Journal:  Cancer Metab       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.